Geertsen PF - Search Results

1

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.

Soerensen AV, Donskov F, Hermann GG, Jensen NV, Petersen A, Spliid H, Sandin R, Fode K, Geertsen PF. Soerensen AV, et al. Among authors: geertsen pf. Eur J Cancer. 2014 Feb;50(3):553-62. doi: 10.1016/j.ejca.2013.10.010. Epub 2013 Nov 8. Eur J Cancer. 2014. PMID: 24215846 Free article.

2

Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.

Geertsen PF, Hermann GG, von der Maase H, Steven K. Geertsen PF, et al. J Clin Oncol. 1992 May;10(5):753-9. doi: 10.1200/JCO.1992.10.5.753. J Clin Oncol. 1992. PMID: 1569448 Clinical Trial.

3

In vitro production of TNF-alpha, IL-1 beta and IL-6 by mononuclear blood cells of patients with renal cell carcinoma undergoing rIL-2 treatment. Relation between clinical response and TNF-alpha production.

Hermann GG, Zeuthan J, Geertsen PF, Claesson MH. Hermann GG, et al. Among authors: geertsen pf. Cytokine. 1992 Mar;4(2):144-50. doi: 10.1016/1043-4666(92)90049-w. Cytokine. 1992. PMID: 1633263

4

Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.

Hermann GG, Geertsen PF, von der Maase H, Steven K, Andersen C, Hald T, Zeuthen J. Hermann GG, et al. Among authors: geertsen pf. Cancer Res. 1992 Feb 1;52(3):726-33. Cancer Res. 1992. PMID: 1732060

5

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma.

Hermann GG, Geertsen PF, von der Maase H, Zeuthen J. Hermann GG, et al. Among authors: geertsen pf. Cancer Immunol Immunother. 1991;34(2):111-4. doi: 10.1007/BF01741344. Cancer Immunol Immunother. 1991. PMID: 1760814 Free PMC article.

6

Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.

von der Maase H, Geertsen P, Thatcher N, Jasmin C, Mercatello A, Fosså SD, Symann M, Stoter G, Nagel G, Israel L, et al. von der Maase H, et al. Eur J Cancer. 1991;27(12):1583-9. doi: 10.1016/0277-5379(91)90419-e. Eur J Cancer. 1991. PMID: 1782066 Clinical Trial.

7

[Interleukin-2 based immunotherapy of cancer].

Geertsen PF, Hermann GG, Claësson MH, Steven K, Zeuthen J, von der Maase H. Geertsen PF, et al. Ugeskr Laeger. 1990 Nov 19;152(47):3513-7. Ugeskr Laeger. 1990. PMID: 2256204 Review. Danish.

8

A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium.

Geertsen PF, Sengeløv L, Larsen SK, von der Maase H. Geertsen PF, et al. Eur J Cancer. 1993;29A(3):347-50. doi: 10.1016/0959-8049(93)90383-q. Eur J Cancer. 1993. PMID: 8398332 Clinical Trial.

9

Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.

Schmidt H, Geertsen PF, Fode K, Rytter C, Bastholt L, von der Maase H. Schmidt H, et al. Among authors: geertsen pf. Melanoma Res. 2000 Feb;10(1):66-77. Melanoma Res. 2000. PMID: 10711642 Clinical Trial.

10

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma.

Geertsen PF, Gore ME, Negrier S, Tourani JM, von der Maase H. Geertsen PF, et al. Br J Cancer. 2004 Mar 22;90(6):1156-62. doi: 10.1038/sj.bjc.6601709. Br J Cancer. 2004. PMID: 15026795 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters